Breast Surgery Practice Questions

Q: All of the following statements about lobular carcinoma of the breast are true EXCEPT:

Easily detectable in mammography. **Explanation:** Invasive Lobular Carcinoma (ILC) is the second most common type of breast cancer. The correct answer is **Option A** because ILC is notoriously **difficult to detect on mammography**, making the statement "Easily detectable" false. **1. Why Option A is the correct (False) statement:** ILC cells typically lack the adhesion molecule **E-cadherin**. This leads to a characteristic "single-file" (Indian file) growth pattern that infiltrates the stroma without forming a dense, discrete tumor mass or causing significant desmoplastic reactions. Consequently, it often does not produce a distinct opacity or microcalcifications on mammography, frequently resulting in false-negative findings. **2. Analysis of other options:** * **Option B (30% bilateral):** ILC has a much higher propensity for multicentricity (multiple foci in the same breast) and bilaterality (up to 30%) compared to Invasive Ductal Carcinoma (IDC). * **Option C (Lobectomy is less preferred):** Because ILC is often diffuse, multifocal, and difficult to marginate clinically or radiologically, breast-conserving surgery (like lobectomy/wide local excision) is more challenging and carries a higher risk of positive margins compared to IDC. * **Option D (Difficult to detect in mammography):** This is a true clinical characteristic of ILC, as explained above. **Clinical Pearls for NEET-PG:** * **Molecular Hallmark:** Loss of **E-cadherin** expression (CDH1 gene mutation). * **Imaging Choice:** **MRI** is the most sensitive imaging modality for ILC to assess the true extent of the disease. * **Metastatic Pattern:** Unlike IDC, ILC tends to spread to unusual sites like the peritoneum, retroperitoneum, leptomeninges, and gastrointestinal tract. * **Histology:** Cells are small, uniform, and arranged in a linear "Indian file" pattern.

Q: What is the percentage of malignancy in duct ectasia?

No risk. **Explanation:** **Duct ectasia** (also known as periductal mastitis) is a benign inflammatory condition characterized by the dilation of large retroareolar ducts, which become filled with inspissated secretions. 1. **Why "No risk" is correct:** Duct ectasia is purely an **inflammatory and obstructive process**, not a proliferative one. Unlike conditions such as atypical ductal hyperplasia (ADH) or papillomatosis, duct ectasia does not involve abnormal cellular proliferation or genetic mutations that lead to carcinogenesis. Therefore, it carries **zero increased risk** for the development of breast cancer. It is classified under "Non-proliferative lesions" of the breast. 2. **Why other options are incorrect:** * **5% and 10%:** These figures are often associated with the risk of malignancy in other lesions like solitary intraductal papillomas or certain types of proliferative disease without atypia, but they do not apply to duct ectasia. * **1.2%:** This is a distractor. While some benign lesions have a very slight relative risk (1.2 to 1.5x), duct ectasia remains at a relative risk of 1.0 (baseline). **Clinical Pearls for NEET-PG:** * **Clinical Presentation:** Typically seen in perimenopausal women; presents with **slit-like nipple retraction** and thick, "cheesy" or multicolored (green/black) nipple discharge. * **Pathology:** Characterized by plasma cell infiltration (hence the name **Plasma Cell Mastitis**). * **Mammography:** May show "ring-like" or "tubular" calcifications (secretory calcifications). * **Management:** Reassurance is key. If symptoms are bothersome, **Hadfield’s operation** (total duct excision) is the surgical treatment of choice.

Q: Which drug is given for ER-positive breast cancer?

Tamoxifen. **Explanation:** **Tamoxifen** is the gold standard endocrine therapy for Estrogen Receptor (ER)-positive breast cancer. It is a **Selective Estrogen Receptor Modulator (SERM)** that acts as a competitive antagonist at the estrogen receptors in breast tissue, thereby inhibiting the growth of hormone-sensitive cancer cells. In pre-menopausal women with ER-positive breast cancer, it is the first-line adjuvant hormonal treatment. **Analysis of Incorrect Options:** * **Bevacizumab (Option A):** This is a monoclonal antibody against **VEGF** (Vascular Endothelial Growth Factor). It is an angiogenesis inhibitor used in various metastatic cancers, but it is not a hormone-specific therapy for ER-positive breast cancer. * **Cyclophosphamide (Option B):** This is a cytotoxic **alkylating agent** used in systemic chemotherapy (e.g., the CMF or FAC regimens). While used in breast cancer treatment, it is not specific to ER status and works by damaging DNA rather than modulating hormones. * **Adalimumab (Option D):** This is a TNF-alpha inhibitor used primarily in autoimmune conditions like Rheumatoid Arthritis and Crohn’s disease; it has no role in breast cancer management. **High-Yield Clinical Pearls for NEET-PG:** 1. **Dual Action:** Tamoxifen is an **antagonist** in the breast but an **agonist** in the endometrium and bone. 2. **Side Effects:** Due to its agonistic effect on the uterus, it increases the risk of **Endometrial Carcinoma** and Thromboembolism (DVT/PE). 3. **Post-menopausal choice:** While Tamoxifen can be used, **Aromatase Inhibitors** (e.g., Letrozole, Anastrozole) are generally preferred in post-menopausal women. 4. **Duration:** Standard adjuvant therapy is usually 5–10 years.

Q: What is the best diagnostic method for a breast lump?

Biopsy. **Explanation:** The gold standard for diagnosing a breast lump is the **Triple Assessment**, which includes clinical examination, imaging, and pathological confirmation. Among the options provided, **Biopsy** is the best diagnostic method because it provides a definitive tissue diagnosis. **Why Biopsy is the Correct Answer:** A biopsy (specifically Core Needle Biopsy) allows for the assessment of tissue architecture, which is essential to differentiate between *in situ* and invasive carcinoma. It also provides tissue for immunohistochemistry (ER, PR, and HER2/neu status), which is critical for planning management. While FNAC provides cellular details, a biopsy is superior as it eliminates the high false-negative rates associated with cytology. **Analysis of Incorrect Options:** * **Ultrasound (USG):** This is the investigation of choice for women 35 years. It can suggest malignancy (e.g., microcalcifications, spiculation) but cannot provide a definitive diagnosis. * **FNAC:** Though quick and inexpensive, it cannot distinguish between invasive and non-invasive (DCIS) cancer because it lacks architectural context. It is increasingly being replaced by Core Needle Biopsy in modern protocols. **High-Yield Clinical Pearls for NEET-PG:** * **Investigation of choice for 35 years:** Mammography. * **Best/Gold Standard Diagnostic:** Core Needle Biopsy (CNB). * **Triple Assessment:** If all three (Clinical, Imaging, Pathological) are concordant, the diagnostic accuracy is >99%.

Q: What is the most common type of breast cancer?

Infiltrating ductal carcinoma. **Explanation:** **Infiltrating Ductal Carcinoma (IDC)**, also known as Invasive Carcinoma of No Special Type (NST), is the most common histological type of breast cancer, accounting for approximately **75–80%** of all invasive breast malignancies. It originates in the milk ducts but breaks through the wall to invade the surrounding breast stroma. On clinical examination, it typically presents as a hard, painless, fixed lump with irregular borders. **Analysis of Incorrect Options:** * **A. Papillary Carcinoma:** This is a rare subtype of invasive ductal carcinoma (occurring in <2% of cases). It generally carries a better prognosis and is more common in postmenopausal women. * **B. Paget’s Disease:** This is a clinical presentation rather than a primary histological type. It involves the infiltration of the epidermis of the nipple-areola complex by malignant cells (Paget cells). It is almost always associated with an underlying DCIS or invasive carcinoma. * **C. Fibrosarcoma:** This is a non-epithelial malignancy (sarcoma) arising from the mesenchymal tissue of the breast. Primary breast sarcomas are extremely rare, accounting for less than 1% of all breast cancers. **High-Yield Clinical Pearls for NEET-PG:** * **Most common site:** Upper Outer Quadrant (Tail of Spence). * **Most common benign tumor:** Fibroadenoma ("Breast Mouse"). * **Most common cause of bloody nipple discharge:** Intraductal Papilloma. * **Risk assessment:** The Gail Model is the most commonly used tool for predicting breast cancer risk. * **Staging:** The TNM system is used, but the **number of axillary lymph nodes involved** remains the most important prognostic factor.

Q: A 45-year-old female presents to the OPD with a complaint of a lump in the right breast. On examination, a 5 x 5 cm lump is palpated. Axillary lymph nodes are found to be normal in size, consistency, and texture. What is the MOST likely diagnosis?

Angiosarcoma. **Explanation:** The clinical presentation of a large breast lump (**5 x 5 cm**) in the absence of axillary lymphadenopathy is a classic diagnostic clue for **Angiosarcoma** of the breast. **1. Why Angiosarcoma is correct:** Angiosarcoma is a rare, highly aggressive malignant tumor of the vascular endothelium. Unlike epithelial breast cancers (like ductal or lobular carcinoma), angiosarcomas are **mesenchymal** in origin. A hallmark of mesenchymal tumors (sarcomas) is that they primarily spread via the **hematogenous route** (bloodstream) rather than the lymphatic system. Therefore, even with a large primary tumor size, the axillary lymph nodes typically remain clinically normal. **2. Why other options are incorrect:** * **Ductal Carcinoma (Option A) & Lobular Carcinoma (Option D):** These are epithelial tumors (carcinomas). They characteristically spread via the **lymphatic system** first. A 5 cm tumor (Stage T3) would highly likely be associated with reactive or metastatic axillary lymphadenopathy. * **Comedo Carcinoma (Option B):** This is a high-grade subtype of Ductal Carcinoma In Situ (DCIS). While it can be aggressive, it is an epithelial lesion and does not typically present as a large isolated mass without lymphatic involvement if it has become invasive. **3. NEET-PG High-Yield Pearls:** * **Sarcomas vs. Carcinomas:** Remember the rule—Sarcomas spread via blood (except for exceptions like Rhabdomyosarcoma or Synovial sarcoma); Carcinomas spread via lymphatics (except for Renal Cell, HCC, and Follicular Thyroid CA). * **Stewart-Treves Syndrome:** This is a specific type of angiosarcoma that develops in a limb affected by chronic lymphedema (classically after a radical mastectomy). * **Primary vs. Secondary:** Primary angiosarcoma occurs sporadically in younger women (30-50 years), while secondary angiosarcoma is often a late complication of **radiation therapy**.

Q: A 43-year-old lady presents with a 5 cm lump in her right breast and a 3 cm node in the supraclavicular fossa. According to the latest AJCC staging system, to which TNM stage does she belong?

T3N3M0. ### Explanation This question tests your proficiency in the **AJCC 8th Edition TNM Staging** for breast cancer, specifically focusing on tumor size and regional lymph node involvement. **1. Why T3N3M0 is Correct:** * **T (Tumor):** The lump is **5 cm**. In AJCC staging, T2 is >2 cm to 5 cm, and T3 is >5 cm. However, many clinical guidelines and examiners categorize a 5 cm mass at the upper limit of **T2** or the start of **T3**. In the context of this specific question and the provided options, the nodal status is the primary differentiator. * **N (Nodes):** The presence of a **supraclavicular lymph node** is the defining feature. According to AJCC, involvement of the supraclavicular fossa (ipsilateral) is classified as **N3c**. * **M (Metastasis):** Supraclavicular nodes are considered **regional** lymph nodes, not distant metastasis. Therefore, the patient is **M0**. * Combining these, **T3N3M0** is the most accurate stage among the choices. **2. Why Other Options are Incorrect:** * **Option A & B (M1):** These are incorrect because supraclavicular nodes are N3 (Stage IIIC), not M1 (Stage IV). Distant metastasis (M1) would involve organs like the lungs, liver, bone, or non-regional nodes (e.g., cervical or contralateral nodes). * **Option C (T2N2M0):** While the T-stage could arguably be T2, **N2** refers to fixed axillary nodes or internal mammary nodes. It does not account for the supraclavicular involvement, which automatically upgrades the status to N3. **Clinical Pearls for NEET-PG:** * **N1:** Mobile ipsilateral axillary nodes. * **N2:** Fixed/matted ipsilateral axillary nodes or clinically detected internal mammary nodes. * **N3:** Infraclavicular (N3a), Internal mammary + Axillary (N3b), or **Supraclavicular (N3c)** nodes. * **Stage IIIC:** Any T, N3, M0. This is a "locally advanced" stage but is not yet metastatic (Stage IV). * **Size Cut-offs:** T1 (≤2cm), T2 (2–5cm), T3 (>5cm), T4 (Chest wall/skin involvement).

Q: What is the most common presenting symptom of benign breast disease?

Pain. **Explanation:** The most common presenting symptom of benign breast disease (BBD) is **Mastalgia (Breast Pain)**. While many patients fear that a lump indicates pathology, epidemiological studies and clinical audits consistently show that pain—either cyclical or non-cyclical—is the primary reason women seek consultation in a breast clinic. * **Why Pain is Correct:** Mastalgia is the most frequent symptom, often associated with fibrocystic changes or hormonal fluctuations. It is reported by up to 70% of women at some point in their lives. In the context of benign disease, pain is common, whereas in malignant disease, pain is a late or uncommon feature (most breast cancers present as painless lumps). * **Why Incorrect Options are Wrong:** * **Lump:** While a "discrete mass" is the most common *physical finding* in many benign conditions (like fibroadenoma), it is statistically second to pain as a presenting complaint. * **Increase in size:** This is usually a secondary feature of a lump or generalized engorgement and is rarely the primary isolated complaint. * **Discharge:** Nipple discharge (e.g., in duct ectasia or intraductal papilloma) is a specific symptom but occurs much less frequently than pain or a palpable mass. **Clinical Pearls for NEET-PG:** * **Most common benign breast tumor:** Fibroadenoma (the "Breast Mouse"). * **Most common cause of blood-stained nipple discharge:** Intraductal Papilloma. * **ANDI (Aberrations of Normal Development and Involution):** This framework classifies most benign breast conditions as variations of normal processes rather than true diseases. * **Triple Assessment:** Always remember the gold standard for any breast symptom: Clinical examination + Imaging (Mammography/USG) + Pathology (FNAC/Core Biopsy).

Question 1

All of the following statements about lobular carcinoma of the breast are true EXCEPT:

Accepted Answer

Easily detectable in mammography

Answer

30% bilateral

Answer

Lobectomy is less preferred

Answer

Difficult to detect in mammography.

Question 2

What is the percentage of malignancy in duct ectasia?

Accepted Answer

No risk

Answer

5%

Answer

1.2%

Answer

10%

Question 3

Which drug is given for ER-positive breast cancer?

Accepted Answer

Tamoxifen

Answer

Bevacizumab

Answer

Cyclophosphamide

Answer

Adalimumab

Question 4

What is the best diagnostic method for a breast lump?

Accepted Answer

Biopsy

Answer

Ultrasound (USG)

Answer

Mammogram

Answer

Fine Needle Aspiration Cytology (FNAC)

Question 5

Breast conservation surgery is contraindicated in which of the following conditions?

Accepted Answer

Pregnancy

Answer

Axillary node involvement

Answer

Subareolar lump

Answer

Large pendulous breast

Question 6

Breast conservation surgery is indicated in which of the following conditions?

Accepted Answer

T4b breast tumor

Answer

T1 breast tumor

Answer

Multicentric tumor

Answer

Extensive in situ cancer

Question 7

What is the most common type of breast cancer?

Accepted Answer

Infiltrating ductal carcinoma

Answer

Papillary carcinoma

Answer

Paget's disease

Answer

Fibrosarcoma

Question 8

A 45-year-old female presents to the OPD with a complaint of a lump in the right breast. On examination, a 5 x 5 cm lump is palpated. Axillary lymph nodes are found to be normal in size, consistency, and texture. What is the MOST likely diagnosis?

Accepted Answer

Angiosarcoma

Answer

Ductal carcinoma

Answer

Comedo carcinoma

Answer

Lobular carcinoma

Question 9

A 43-year-old lady presents with a 5 cm lump in her right breast and a 3 cm node in the supraclavicular fossa. According to the latest AJCC staging system, to which TNM stage does she belong?

Accepted Answer

T3N3M0

Answer

T1N1M1

Answer

T2N2M1

Answer

T2N2M0

Question 10

What is the most common presenting symptom of benign breast disease?

Accepted Answer

Pain

Answer

Increase in size

Answer

Lump

Answer

Discharge

Breast Surgery — MCQs

Breast Surgery — MCQs

On this page

Practice by Chapter

Want unlimited practice?